Formic Acid

Formic Acid

SCHEMBL21351973

O=C(O)c1cc(O)ncc1Br.O=CO

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C4 P17516 2/20 0.39
AKR1C3 P42330 2/20 0.39
AKR1C2 P52895 2/20 0.39
AKR1C1 Q04828 2/20 0.39
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
PTPN1 P18031 4/20 0.37
PTPN2 P17706 1/20 0.37
PTPN6 P29350 1/20 0.37
KDM4E B2RXH2 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21826652 0.93 AKR1C4 (0.44) AKR1C4AKR1C3AKR1C2AKR1C1TSHR
SCHEMBL2249284 0.75 HSD17B10 (0.43) AKR1C4AKR1C3AKR1C2AKR1C1TSHR
SCHEMBL8220004 0.73 KDM4E (0.60) AKR1C4AKR1C3AKR1C2AKR1C1TSHR
SCHEMBL23854026 0.72 CA1 (0.45) TSHRHSD17B10LCKPTPN1PTPN2
SCHEMBL21351974 0.72 HSD17B10 (0.39) AKR1C4AKR1C3AKR1C2AKR1C1TSHR
SCHEMBL22717759 0.72 KDM4E (0.44) AKR1C4AKR1C3AKR1C2AKR1C1TSHR
SCHEMBL1998749 0.72 NAPRT (0.42) AKR1C4AKR1C3AKR1C2AKR1C1TSHR
SCHEMBL4790109 0.72 GABRP (0.56) AKR1C4AKR1C3AKR1C2AKR1C1TSHR
SCHEMBL14901955 0.72 HSD17B10 (0.44) AKR1C4AKR1C3AKR1C2AKR1C1TSHR
SCHEMBL31220104 0.72 NAPRT (0.42) AKR1C4AKR1C3AKR1C2AKR1C1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 AKR1C4 1654/4885AKR1C3 1560/4885AKR1C2 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.